The protein known as macrophage migration inhibitory factor (MIF) was one of the first cytokines to be discovered and was described 30 years ago to be a T-cellderived factor that inhibited the random migration of macrophages in vitro. A much broader role for MIF has emerged recently as a result of studies that have demonstrated it to be released from the anterior pituitary gland in vivo. MIF also is the first protein that has been identified to be secreted from monocytes/macrophages upon glucocorticoid stimulation. Once released, MIF acts to "override" or counter-regulate the suppressive effects of glucocorticoids on macrophage cytokine production. We report herein that MIF plays an important regulatory role in the activation of T cells induced by mitogenic or antigenic stimuli. Activated T cells produce MIF and neutralizing anti-MIF antibodies inhibit T-cell proliferation and interleukin 2 production in vitro, and suppress antigendriven T-cell activation and antibody production in vivo. T cells also release MIF in response to glucocorticoid stimulation and MIF acts to override glucocorticoid inhibition of T-cell proliferation and interleukin 2 and interferon y production. These studies indicate that MIF acts in concert with glucocorticoids to control T-cell activation and assign a previously unsuspected but critical role for MIF in antigenspecific immune responses.
The protein that has been described historically as "macrophage migration inhibitory factor" (MIF) was discovered 30 years ago as one of the first soluble mediators, or lymphokines, to be produced by activated lymphocytes (1, 2) . In more recent studies, MIF has been found to be released as a hormone by the anterior pituitary gland (3, 4) , and by macrophages in response to a variety of pro-inflammatory stimuli (5) . Circulating MIF levels increase during physiological stress or as a consequence of systemic inflammatory conditions such as endotoxemia (3, 6) . MIF has been shown to play a critical role in septic shock and in the delayed-type hypersensitivity reaction, as neutralizing antibodies to MIF suppress these responses in experimental animals (3, 7) . A unique property of MIF is that it also is released from monocytes/macrophages in response to stimulation by glucocorticoids. Once released, MIF acts to "override" or counter-regulate the immunosuppressive effects of glucocorticoids on macrophage/cytokine production in vitro and on lipopolysaccharide-induced lethality in vivo, suggesting that MIF may act as an endogenous, counter-regulatory mediator for glucocorticoid action within the immune system (6) .
The initiation of an antigen-specific immune response is dependent in large part on the activation and differentiation of T cells. This process is in turn controlled by antigen-specific stimuli that act in concert with cytokines and other hostderived, immune cell mediators. In the present study, we have investigated the role of MIF expression in T-cell immunity and report experiments that assign a previously unsuspected but critical role for MIF in antigen-specific immune responses.
MATERIALS AND METHODS
Reagents. Mouse or human recombinant MIF (rMIF) was prepared from the Escherichia coli pETllb expression system, purified free of endotoxin, refolded, and shown to be bioactive by macrophage migration inhibition and augmentation of macrophage nitric oxide (NO) production (8) . rMIF contained <0.5 fg lipopolysaccharide/ng of protein as assessed by the Limulus amoebocyte assay (BioWhittaker). Anti-MIF IgG was prepared from rabbit antiserum raised to mouse rMIF and was shown previously to neutralize MIF activity in vivo (3) . Anti-MIF and nonimmune IgG were isolated from serum by protein-G affinity chromatography following the manufacturer's instructions (Pharmacia). The neutralizing anti-mouse interleukin 2 (IL-2) mAb and the IL-2, IL-10, and interferon-'y ELISA kits were from Genzyme. The IL-4 ELISA kit was from Endogen (Cambridge, MA).
Reverse transcription (RT)-PCR studies used the intronspanning mouse MIF primer pair: 5'-CCATGCCTATGTTC-ATCGTG-3' and 5'-GAACAGCGGTGCAGGTAAGTG-3' (381 bp) (3), the mouse IL-2 primer pair: 5'-AGCTCGCATC-CTGTGTCACA-3' and 5'-AGAAGGCTATCCATCTC-CTC-3' (464 bp) (9), the IL-2 receptor (a-subunit) primer pair: 5 '-CAACAGACATGCAGAAGCCA-3' and 5 '-AGGAG-GAGGATGCTGATGAG-3' (451 bp) (10) , and the mouse f3-actin primer pair: 5'-AGGACTCCTATGTGGGTGAC-3' and 5'-GCCACAGGATTCCATACCCA-3' (671 bp) (1 1).
T-Cell Preparation and Culture. Mouse T cells were prepared from the spleens of BALB/c mice (19-21 g ), pooled, and the red blood cells lysed by treatment with 0.8% NH4Cl (12) . Mouse T cells were purified by passage over a T-cell enrichment column (R & D Systems) and were >95% pure as assessed by flow cytometry analysis after staining with anti-CD3 antibody (PharMingen). Human T cells were purified from the peripheral blood of tetanus toxoid-immunized individuals by chromatography on T-cell enrichment columns (R & D Systems), washed, and cultured in RPMI 1640 medium/ 10% fetal bovine serum (FBS).
MIF Expression Studies. Purified mouse T cells were cultured in 24-well flat bottom plates (2 x 106 cells/ml) in RPMI gentamicin. Cells were incubated alone as control in anti-CD3 mAb-coated plates (coated at 5 ,ug/ml), or in the presence of phorbol 12-myristate 13-acetate (PMA) (1 ng/ml) together with ionomycin (5 ng/ml) (PMA/ION) (13) . For Northern blot analysis, the cells were harvested at the indicated times and the total RNA isolated with RNAzol-B (Tel-Test, Friendswood, TX). RNA (7.5 ,ug) was electrophoresed through 1.5% agarose-formaldehyde gels, transferred onto nylon membranes (Schleicher & Schuell), and hybridized sequentially with cDNA probes for mouse MIF (3), IL-2 (9), and ,3-actin (11) (Quick Hyb; Stratagene). Probes were labeled with 32P by the random-priming method (Megaprime kit, Amersham). Autoradiography was performed at room temperature for 2-6 hr using DuPont Reflection films and intensifying screens.
For measurements of MIF protein, conditioned medium was obtained from control, anti-CD3, and PMA/ION-stimulated mouse T cells prepared as described above and analyzed by sandwich ELISA employing a monoclonal anti-MIF capture antibody, a polyclonal rabbit anti-mouse MIF detector, and purified mouse rMIF as standard (6, 8 For RT-PCR analysis, cultured T cells were harvested 24 hr after stimulation and lysed in RNAzol-B (Tel-test). cDNA was prepared from 0.5-1.0 ,ug of total RNA using 0.25 ng of oligo-(dT)12_18 and Superscript II following the manufacturer's protocol (GIBCO/BRL). Two ,ll aliquots of cDNA then were amplified by PCR in a Perkin-Elmer model 9600 thermal cycler using the primers listed above and the following cycling program: denaturation for 1 min at 95°C, annealing for 10 sec at 55°C, and extension for 20 sec at 72°C.
THi and TH2 T-Cell Clones. The preparation, in vitro propagation, and characteristics of the TH1 (LNC2, B1O/B1) and TH2 (DlOG4.1, L1/1) lines have been described (15) (16) (17) (18) . T-cell clones were cultured at 1 x 106 cells/ml in RPMI 1640 medium supplemented with 10% FBS, 2 mM glutamine, and 50 ,ug/ml gentamicin. Twenty-four hours after stimulation with concanavalin A (Con A) at 5 ,ug/ml, collected from mice prior to sacrifice and analyzed by sandwich ELISA employing immobilized RNase and an anti-mouse IgG secondary antibody linked to alkaline phosphatase. Absorbance signals were converted to ng/ml of antibody by comparison with a mouse IgG standard curve.
MIF/Glucocorticoid Interaction Studies. T cells were purified from human peripheral blood and 1 x 106 cells per well incubated with dexamethasone (10-8 M) alone or with dexamethasone (10-8 M) plus human rMIF (1-10 ng/ml). After 2 hr, the cultures were transferred to 96-well plates containing Con A (10 [kg/ml), tetanus toxoid (2 ,ug/ml), or immobilized anti-CD3 antibody together with 1 X 104 antigen-presenting cells per well. The antigen-presenting cells were prepared from autologous peripheral blood and treated with mitomycin-C as described (19) . After 5 days of culture, the cultures were pulsed with 1 ,uCi [3H]thymidine and harvested 12 hr later for scintillation counting. IL-2 and IFN-'y production were measured by ELISA in supernatants harvested 24 hr after stimulation.
RESULTS
The expression of MIF was first analyzed by Northern blotting of RNA obtained from purified mouse T cells that had been activated by incubation with anti-CD3 antibody or with PMA/ ION. A prominent induction in the expression of MIF mRNA was observed over time (Fig. 1A) . These stimulation conditions also resulted in an increase in the expression of IL-2 mRNA (20) ; however, the kinetics of the MIF response differed from that of IL-2 by reaching and maintaining high levels of expression later in time. Anti-CD3 antibody also was a more potent stimulator of MIF mRNA than of IL-2 mRNA expression. A similar induction in the expression of MIF mRNA was observed in the mouse T-cell line LBRM and in human peripheral blood T cells after treatment with anti-CD3 or PMA/ION (data not shown).
MIF is an abundant, preformed constituent of the anterior pituitary gland and of resting, unstimulated monocytes/ macrophages (3) (4) (5) . Preformed MIF also has been detected by Western blotting in cell lysates prepared from unstimulated, primary mouse T cells and the human Jurkat T-cell line (5) . By ELISA, the intracellular MIF content was determined to be 4.0 ± 1.2 fg per cell for primary mouse T cells and 170 ± 25 fg per cell for the mouse LBRM T-cell line. By comparison, the MIF content of mouse thioglycollate-elicited peritoneal macrophages and RAW 264.7 macrophages was found to be 2.0 ± 0.6 fg per cell and 120 ± 20 fg per cell, respectively. Primary T cells released MIF into the medium after incubation with anti-CD3 antibody or PMA/ION (Fig. 1B) . Stimulation with PMA/ION produced a prominent MIF release response that was detectable within 4 hr. MIF levels in medium were 10 ng/ml at 4 hr and 17.5 ng/ml at 24 hr, but decreased thereafter.
A 1000-j- (Fig. 24) . As anticipated, anti-IL-2 antibody also inhibited T-cell proliferation under these experimental conditions (21) . The addition of anti-MIF together with anti-IL-2 antibodies was not found to significantly increase the inhibitory effect of anti-IL-2 antibody alone. Anti-MIF antibody also inhibited the in vitro antigendriven proliferation of primed T cells isolated from spleens 12 days after immunization of mice with RNase (Fig. 2B) .
To further examine the functional relationship between IL-2 and MIF on T-cell proliferation, we measured IL-2 secretion by anti-CD3-activated T cells incubated with either anti-MIF or an IgG control. As shown in Fig. 2C , anti-MIF treatment produced a significant decrease in the IL-2 released into culture supernatants by anti-CD3-treated T cells. The inhibitory effect of anti-MIF IgG on IL-2 expression occurred in part at the level of IL-2 gene transcription as shown by RT-PCR analysis of T cells treated with anti-CD3 + anti-MIF (Fig. 2D) .
In contrast to the independent effect of IL-2 on T-cell proliferation (22, 23) , the addition of purified, bioactive rMIF (0.001-100 ng/ml) to resting, unstimulated T cells was not itself mitogenic and had only a small, augmenting effect on T-cell mitogenesis induced by anti-CD3 antibody (increasing [3H]thymidine incorporation by -10%). Exogenously added MIF did not induce IL-2 expression in naive T cells nor did it increase IL-2 expression above the level already induced by anti-CD3 stimulation, as assessed by RT-PCR or ELISA (data not shown). These data suggest that added MIF has no additional effect on anti-CD3-induced T-cell proliferation or IL-2 release, but that MIF expression is nevertheless a necessary component of the pathway leading to T-cell activation, IL-2 production, and mitogenesis.
Cytokine expression by the T-cell helper subsets TH1 and TH2 critically regulates host effector responses to various antigens (24, 25) . THi cells produce IL-2, IFN-,y, and tumor necrosis factor 13 (lymphotoxin), and promote cell-mediated immune responses that play an important role in the control of infection caused by various intracellular pathogens. Cells of the TH2 subset produce IL-4, IL-5, and IL-10, which favor the development of humoral immunity. We prepared THi and TH2 clones from BALB/c mice and measured their expression of MIF mRNA and protein after incubation with Con A. A prominent induction of MIF mRNA was observed upon Con A stimulation of the TH2, but not the TH1 clones (Fig. 3A) . Whereas low levels of MIF protein were detectable in the conditioned medium of all four T-cell clones in the absence of mitogen, only the TH2 clones released MIF protein after stimulation with Con A (Fig. 3B) .
To examine the role of MIF expression in the induction of a primary immune response in vivo, we studied the effect of passive immunotherapy with anti-MIF IgG in mice immunized with RNase. Naive mice received a single, i.p. injection of RNase in Freund's complete adjuvant and were then treated at 3-day intervals with either anti-MIF or control IgG. After 12 days, T cells were purified from the spleens of antigenprimed mice and tested for their proliferative response to RNase in vitro. Serum also was obtained and tested for a specific anti-RNase immunoglobulin response. As shown in hibitory effect of anti-MIF antibody on the development of humoral immunity in vivo reinforces the in vitro observations that MIF is a prominent secretory product of activated TH2 lymphocytes. We also studied the effect of administering rMIF (5-50 mg/kg i.p., qd) to mice during primary immunization with RNase. However, no significant changes in either the T-cell proliferative response or the primary antibody titer to antigen were observed when the rMIF-treated group was compared with controls (data not shown). That rMIF showed no significant augmenting effect on a primary immune response in vivo is consistent with the in vitro data and suggests that exogenously added MIF provides little or no enhancing activity over the MIF produced endogenously during immune cell activation.
The marked suppression of T-cell proliferation and antibody response by anti-MIF treatment nevertheless implied to us that MIF plays a critical role in the normal T-cell response to antigen. In the case of macrophages, recent studies have shown that MIF functions in vitro and in vivo as a glucocorticoidinduced, counter-regulatory mediator to override the inhibitory effect of steroids on macrophage activation and cytokine expression (6) . As reported for macrophages, physiological levels of glucocorticoids also induced MIF secretion from cultured T cells (6) . MIF concentrations were determined by ELISA to be 1.4 ± 0.2 ng/ml and 4.7 ± 0.8 ng/ml in supernatants of cultured primary or LBRM mouse T cells, respectively, after incubation with low concentrations of dexamethasone (10-10 M for 24 hr). We next examined whether rMIF affected the glucocorticoid-mediated suppression of mitogen-or anti- (26) . Thus, rMIF was found to override, in a dose-dependent fashion, the glucocorticoid-mediated inhibition of primary human T-cell proliferation (Fig. 4B ). This effect also was reflected in the ability of rMIF to override glucocorticoid inhibition of T-cell IL-2 and IFN-,y production (Fig. 4C) .
DISCUSSION
Despite the long-standing association of MIF with activated T cells, the precise role of MIF in T-cell responses has remained undefined. Certain of the original preparations of cloned human MIF were unpurified and were reported subsequently to contain significant quantities of mitogenic contaminants (27, 28) . Recently, however, both the mouse and human MIF proteins have been expressed in high yield, purified in a bioactive form, and become available for use in biological studies (3, 8) .
MIF normally circulates at basal levels in serum and additional MIF is secreted both as a product of the anterior pituitary gland and of activated monocytes/macrophages in response to various invasive stimuli (3, 6) . Uniquely, MIF also is released from macrophages that have been stimulated with glucocorticoids. Glucocorticoid-induced MIF secretion follows a bell-shaped dose response curve, decreasing at concentrations of dexamethasone 2 10-8 M. Once released, MIF overrides or antagonizes glucocorticoid suppression of macrophage cytokine production in vitro (i.e., tumor necrosis factor a, IL-1, IL-6, IL-8) and endotoxin lethality in vivo. The magnitude of this effect varies with the concentration of both glucocorticoid and MIF, suggesting that the two mediators act in a mutually counter-regulating manner to control cytokine production and inflammatory responses (6) .
In the present report, we have examined the expression of MIF by T cells and the role of MIF in both mitogen and antigen-driven T-cell responses. Activated T cells express significant quantities of MIF mRNA and protein. Although neutralizing anti-MIF antibodies were found to inhibit T-cell proliferation and IL-2 production-indicating that MIF is a required participant in these responses-purified rMIF was not itself directly mitogenic to either resting or activated T cells. Exogenously added rMIF also showed no significant augmenting effect on the initiation of a primary immune response in vivo. These data are consistent with the interpretation that MIF expression is a necessary component of the pathway leading to T-cell activation, IL-2 production, and mitogenesis. That exogenously-administered rMIF was not seen to exert an increased biological effect furthermore suggests that the endogenous MIF, which is present in serum [at 5-15 ng/ml (6)], and which increases upon immune cell activation, is sufficient to support these responses.
The finding that a major action of MIF is to override the inhibitory effect of glucocorticoids on T-cell activation adds an important dimension to the emerging concept of MIF as a glucocorticoid-induced, counter-regulatory mediator of immune and inflammatory responses. Circulating glucocorticoid levels increase during infection and inflammation and act to downregulate the immune response by inhibiting immune cell activation and cytokine production (29) (30) (31) (32) (33) (34) . Once released by activated T cells or by macrophages, or as a consequence of increasing glucocorticoid levels, MIF would act locally to override the immunosuppressive effects of glucocorticoids, thus enabling a primary immune response to be generated. In this context, it is worthwhile to consider that an anti-MIF therapeutic strategy might serve to increase the immunosuppressive and anti-inflammatory properties of endogenouslyreleased glucocorticoids and thus reduce the requirement for steroid therapy in various autoimmune and inflammatory conditions.
